

The Art and Science of

Managing Melanoma and Non-Melanoma Skin Cancers

May 2-3, 2025

Marriott Medical Center Hotel Houston
6580 Fannin Street, Houston TX 77030



THE UNIVERSITY OF TEXAS
**MD Anderson
Cancer Center**

Making Cancer History®

The Art and Science of Managing Melanoma and Non-Melanoma Skin Cancers Symposium

Friday, May 2, 1 - 6 p.m. - Saturday, May 3, 7 a.m.- 3:45 p.m.

Marriott Medical Center Hotel Houston, 6580 Fannin Street, Houston TX 77030

Target Audience:

Fellows, Advanced Practice Providers and Physicians.

Description:

This conference will utilize presentations and case-based panel discussions to illustrate optimal contemporary approaches used to manage patients with melanoma and non-melanoma skin cancers. It will provide learners with practical and useful examples of how to best manage and treat patients with these diseases.

Learning Objectives:

1. Utilize emerging data about the potential indications, safety, and efficacy of adjuvant therapy for patients with high-risk clinically localized (stage IIB/C) melanoma and stage III melanoma.
2. Describe the rationale for neoadjuvant therapy for patients with stage III melanoma and the prognostic significance of the pathological response to treatment.
3. Summarize treatment options for patients with stage IV melanoma, including in treatment-naive patients and in patients that previously progressed on anti-PD-1-based immunotherapy.
4. Recall the available data about the appropriate sequencing of immunotherapy and targeted therapy in treatment-naive stage IV metastatic melanoma patients with a BRAF V600 mutation.
5. Describe the differences in the presentation and diagnosis of the various nonmelanoma cutaneous cancers (BCC, SCC, Merkel Cell Carcinomas).
6. Examine the indications for immunotherapy in nonmelanoma skin cancers, and the subtleties in response patterns and outcomes.

Accreditation:

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery CC Credit:

Successful completion of this CME activity, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for purpose of granting ABS credit.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Planning Committee Members

Phyu Aung, MD, PhD

Sarah Baig

Angelic Castillo

Michael A Davies, MD, PhD

Kelly Nelson, MD

Devarati Mitra, MD, PhD

Michelle Rohlf, MSN, APRN, FNP-BC, AOCNP

Merrick Ross, MD, FACS

Faculty/Speakers

Roda Amaria, MD

Associate Professor | Melanoma Medical Oncology

Phyu Aung, MD, PhD

Professor | Pathology, Anatomical

Michael Davies, MD, PhD

Professor, Chair | Melanoma Medical Oncology

Ahsan Farooqi, MD, PhD

Assistant Professor

Jeffery Gershenwald, MD

Professor | Surgical Oncology

Isabella Glitza, MD, PhD

Associate Professor | Melanoma Medical Oncology

Neil Gross, MD

Professor | Head & Neck Surgery

Ashley Holder, MD, FACS

Assistant Professor | Surgical Oncology

Alexandra Ikeguchi, MD

Associate Professor | Melanoma Medical Oncology

Jennifer McQuade, MD

Assistant Professor | Melanoma Medical Oncology

Devarati Mitra, MD, PhD

Assistant Professor | Radiation Oncology Department

Kelly Nelson, MD

Professor | Dermatology

Anisha Patel, MD

Associate Professor | Department of Dermatology

Michelle Rohlf, MSN

Mgr, Advanced Practice Provider | Melanoma Medical Oncology

Merrick Ross, BS, MD

Professor | Surgical Oncology

Hussein Tawbi, MD, PhD

Professor | Melanoma Medical Oncology

Carlos Antonio Torres-Cabala, MD, FCAP, FASCP

Professor | Pathology, Anatomical

Guest Speaker



Michael K. Wong, MD, PhD, FRCPC

Medical Oncology, Physician in Chief
Roswell Park Comprehensive Cancer Center

Dr. Wong is a medical oncologist and skin cancer expert, who joined Roswell Park from MD Anderson Cancer Center in Houston, where he was Professor in the Department of Melanoma Medical Oncology and Medical Executive for Integration and Innovative Programs for the MD Anderson Cancer Network.

Day 1 : Friday, May 2

Session 1 : Clinically Localized Disease

Time	Theme and Presentation Title	Presenter/Speaker
1 p.m.	Welcome	Kelly Nelson, MD and Michael Davies, MD
1:10 p.m.	Dermatology: Optimizing Surveillance: Germline Testing and Total Body Photography	Kelly Nelson, MD
1:30 p.m.	Surgery: Surgery for Clinically Localized Disease - What's New?	Merrick Ross, MD
1:50 p.m.	Pathology: The Role of the Pathologist in Patient Management	Phyu Aung, MD
2:05 p.m.	Radiation: What is the Role of Radiation	Devarati Mitra, MD
2:15 p.m.	Medical: Adjuvant Therapy for Clinically Localized Melanoma-Options and Controversies	Michael Davies, MD
2:25 p.m.	Multidisciplinary Panel Case-Based Discussion:	Moderator: Merrick Ross, MD Panelists: Phyu Aung, MD; Michael Davies, MD; Jeffery Gershenwald, MD; Devarati Mitra, MD; Kelly Nelson, MD
3:30 p.m.	Break	

Session 2 : The Multidisciplinary Management of Regionally Metastatic Melanoma

4 p.m.	Medical – Adjuvant and Neo-Adjuvant Therapy: Adjuvant Therapy for Regional Disease-Options and Controversies	Michael Davies, MD
4:30 p.m.	Surgery: The Multidisciplinary Management of Stage III Melanoma	Merrick Ross, MD
4:45 p.m.	Pathology: The Evolving Role of Pathology in Stage III Disease	Carlos Torres-Cabala, MD
5 p.m.	Radiation: Is There a Role for Adjuvant Radiation in Regionally Metastatic Disease	Devarati Mitra, MD
5:15 p.m.	Multidisciplinary Panel Case-Based Discussion	Moderator: Michael Davies, MD Panelists: Rodabe Amaria, MD; Jennifer McQuade, MD; Devarati Mitra, MD; Merrick Ross, MD; Carlos Torres-Cabala, MD
6 p.m.	Adjourn – Welcome Reception (6-7 p.m.)	

Day 2 : Saturday, May 3

Session 3 : New Options, Opportunities, and Challenges for Stage IV Disease

Time	Theme and Presentation Title	Presenter/Speaker
7 a.m.	Continental Breakfast & Onsite Registration	
8 a.m.	Immune Checkpoint Therapy: Immune Checkpoint Blockade-Where Are We Now	Hussein Tawbi, MD
8:20 a.m.	TIL: Cell Therapy for Melanoma-the Next Wave of Immunotherapy	Rodabe Amaria, MD
8:40 a.m.	Targeted Therapeutics: What is the Role of Targeted Therapy for Stage IV Melanoma	Michael Davies, MD
9 a.m.	Radiation: Evolving Role of Radiation Therapy for Stage IV Melanoma	Ahsan Farooqi, MD
9:20 a.m.	Multidisciplinary Panel Case-Based Discussion	Moderator: Rodabe Amaria, MD Panelists: Rodabe Amaria, MD; Michael Wong, MD
10:30 a.m.	Break	

Session 4 : The Art of Melanoma Management

11:00 a.m.	Immuno Therapy Toxicities: Recognizing and Treating Immunotherapy Toxicities	Jennifer McQuade, MD
11:15 a.m.	CNS Disease: Progress in The Management and Outcomes for CNS Disease	Isabella Glitza, MD
11:30 a.m.	Uveal Melanoma: Uveal Melanoma-Progress and Promise	Alexandra Ikeguchi, MD
11:45 a.m.	Multidisciplinary Panel Case-Based Discussion:	Moderator: Jennifer McQuade, MD Panelists: Ahsan Farooqi, MD; Isabella Glitza, MD; Alexandra Ikeguchi, MD; Anisha Patel, MD; Michelle Rohlf, MSN
12:15 p.m.	Lunch	

Day 2 : Saturday, May 3

Session 5 : Multidisciplinary Approaches for Squamous Cell and Merkel Cell Carcinoma

Time	Theme and Presentation Title	Presenter/Speaker
1 p.m.	Session Introduction	Michael Wong, MD
1:05 p.m.	Unique Considerations in the Pathology of cSCC and MCC: Unique Considerations in the Pathology of cSCC and MCC	Phyu Aung, MD
1:15 p.m.	Neoadjuvant and Surgical Therapy of cSCC: Neoadjuvant Immunotherapy for Advanced, Resectable CSCC	Niel Gross, MD
1:30 p.m.	Systemic Therapy of Locally Advanced and Metastatic cSCC: Advances and opportunities in Systemic Therapy for cSCC	Michael Wong, MD
1:45 p.m.	The Role of Radiation Therapy for cSCC: Radiation Therapy in the Management of H&N and Truncal/Extremity cSCC	Ahsan Farooqi, MD
2 p.m.	Multidisciplinary Panel Case-Based Discussion cSCC	Moderator: Michael Wong, MD Panelists: Dr. Ahsan Farooqi, MD Ashley Holder, MD; Alexandra Ikeguchi, MD; Merrick Ross, MD
2:30 p.m.	Surgical Management of Merkel Cell Carcinoma: Advances and Opportunities in Systemic Therapy for MCC	Dr. Merrick Ross
2:45 p.m.	Immunotherapy, Targeted Therapy, and Cytotoxic Chemotherapy of MCC: Breakthroughs for Non-Melanoma Skin Cancers	Michael Wong, MD
3 p.m.	New Approaches to the Radiation Therapy of MCC: New schedules, XRT to 'Rescue IO-refractory MCC'	Devarati Mitra, MD
3:15 p.m.	Multidisciplinary Panel Case-Based Discussion MCC	Moderator: Michael Wong, MD Panelists: Ashley Holder, MD; Alexandra Ikeguchi, MD; Devarati Mitra, MD; Merrick Ross, MD
3:45 p.m.	Final Remarks and Adjourn	

Conference Registration Fees:

MD Anderson Physicians (MD, DOs)

Fee Exempt

MD Anderson RNs/PAs/NPs/ Trainees

Fee Exempt

Cancer Network Members (will be verified)

Fee Exempt

Non-MD Anderson Physicians (MD, DOs)

Postmarked before May 2, 2025: \$150.00

On-Site: \$200.00

Non-MD Anderson RNs/PAs/NPs/ Trainees

Postmarked before May 2, 2025: \$100.00

On-Site: \$125.00

We accept the following forms of payment:

- Credit Cards (MasterCard, VISA, and American Express)
- Check (payable to The University of Texas MD Anderson Cancer Center through U.S. banks only)

Mail checks to:

Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
P.O. Box 301407
Houston, TX 77230-1407

Telephone registrations will not be accepted.


When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form. Once your payment has been made, a receipt can be found in the MyCE tab of your PEP@MD Anderson account.

Refund/Cancellation Policy

The registration fee, minus a \$35.00 administration-handling fee, is refundable if a written request is received on or before Friday, April 11, 2025. No refunds will be granted after these dates. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of Continuing Professional Education (CPE) reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of Continuing Professional Education, is limited to the registration fee. CPE will refund the full registration fee.

The Department of Continuing Professional Education, reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.



Special Assistance

For additional information contact:

Continuing Professional Education
713-792-2223 or toll free at 866-849-5866 or
e-mail: ContinuingEducation@mdanderson.org.

If you have any ADA accommodation needs or need assistance.

Evaluation

A course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. The survey link will be provided during the review course.



THE UNIVERSITY OF TEXAS

MDAnderson
~~Cancer~~ Center

Making Cancer History®